Shares of uniQure (NASDAQ:QURE) traded down 4% during mid-day trading on Thursday following insider selling activity. The company traded as low as $36.32 and last traded at $36.34. 7,539 shares were traded during trading, a decline of 98% from the average session volume of 495,816 shares. The stock had previously closed at $37.87.
Specifically, VP Alexander Edward Kuta III sold 2,229 shares of uniQure stock in a transaction dated Tuesday, September 21st. The stock was sold at an average price of $36.71, for a total value of $81,826.59. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Christian Klemt sold 2,400 shares of uniQure stock in a transaction dated Tuesday, September 21st. The stock was sold at an average price of $38.00, for a total value of $91,200.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 36,732 shares of company stock worth $1,238,993. 2.68% of the stock is owned by corporate insiders.
A number of equities analysts recently weighed in on the company. SVB Leerink reissued a “buy” rating on shares of uniQure in a research note on Tuesday, September 14th. Credit Suisse Group reaffirmed an “outperform” rating and set a $27.46 target price (down previously from $78.00) on shares of uniQure in a research note on Tuesday, July 27th. Zacks Investment Research raised uniQure from a “sell” rating to a “hold” rating in a research note on Friday, July 30th. BTIG Research assumed coverage on uniQure in a research note on Monday, June 14th. They set a “buy” rating and a $46.00 target price on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and set a $95.00 target price (down previously from $100.00) on shares of uniQure in a research note on Tuesday, July 27th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat.com, uniQure currently has a consensus rating of “Buy” and a consensus target price of $59.95.
uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Sunday, July 25th. The biotechnology company reported $8.51 EPS for the quarter, topping analysts’ consensus estimates of $2.97 by $5.54. uniQure had a return on equity of 90.98% and a net margin of 60.66%. The company had revenue of $463.87 million during the quarter, compared to analyst estimates of $212.65 million. As a group, sell-side analysts predict that uniQure will post 6.23 earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of uniQure during the second quarter worth approximately $710,000. Marshall Wace LLP bought a new stake in shares of uniQure during the second quarter valued at approximately $2,262,000. Marshall Wace North America L.P. bought a new stake in shares of uniQure during the second quarter valued at approximately $5,489,000. Morgan Stanley increased its position in shares of uniQure by 114.4% during the second quarter. Morgan Stanley now owns 105,734 shares of the biotechnology company’s stock valued at $3,256,000 after purchasing an additional 56,427 shares during the period. Finally, Sphera Funds Management LTD. bought a new stake in shares of uniQure during the second quarter valued at approximately $5,298,000. Institutional investors own 77.06% of the company’s stock.
About uniQure (NASDAQ:QURE)
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Further Reading: 52-week highs
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.